Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gusacitinib in Systemic Lupus Erythematosus (SLE)
NCT06238531Phase 1Withdrawn
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gusacitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoint: Adverse Events severity and frequency at 12 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
gusacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06238531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238531.